Previous 10 | Next 10 |
Reata Pharmaceuticals (RETA) -8.8% after-hours following news that the Food and Drug Administration's review of its proposed omaveloxolone treatment for Friedreich's ataxia, a rare neuromuscular disorder, concluded that the findings do not strengthen the results of Part 2 of the MOXIe study.R...
Gainers: [[YJ]] +47.8%. [[FRAN]] +27.7%. [[JFU]] +23.2%. [[MESA]] +18.5%. [[WEI]] +17.8%.Losers: [[MOHO]] -23.9%. [[GPS]] -10.5%. [[RETA]] -8.8%. [[BPT]] -7.5%. [[NGMS]] -4.9%. For further details see: YJ, FRAN, MOHO and GPS among after-hours movers
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q3 2020 Earnings Call Nov 9, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Reata Pharmaceuticals, Inc. (RETA) Q3 2020 Earnings Call Transcr...
Reata Pharmaceuticals, Inc. (RETA) Q3 2020 Earnings Conference Call November 09, 2020 08:00 AM ET Company Participants Vinny Jindal - Vice President, Corporate Communications & Strategy Warren Huff - President & Chief Executive Officer Colin Meyer - Chief Research & Development Of...
Reata Pharmaceuticals (RETA) soars 29% in premarket on moderate volume, after announcing that its Phase 3 (CARDINAL) study evaluating bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome, has met its primary and key secondary endpoints at the end of Y...
Reata Pharmaceuticals (RETA): Q3 Non-GAAP EPS of -$1.31 beats by $0.54; GAAP EPS of -$1.94 beats by $0.04.Revenue of $1.4M (-83.0% Y/Y) beats by $0.12M.Press Release For further details see: Reata Pharmaceuticals EPS beats by $0.54, beats on revenue
BARDOXOLONE ACHIEVED THE YEAR 2 PRIMARY AND KEY SECONDARY ENDPOINT S WITH STATISTICALLY SIGNIFICANT IMPROVEMENT S IN EGFR AS COMPARED TO PLACEBO AT WEEK 100 AND WEEK 104 ...
REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME REPORTED LONG TERM EFFICACY DATA FROM EAGLE (OPEN-LABEL EXTENSION ) STUDY ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023